Longboard Pharmaceuticals Completes Enrollment Of Phase 1b/2a PACIFIC Study Evaluating LP352 For The Treatment Of Developmental And Epileptic Encephalopathies
Portfolio Pulse from Happy Mohamed
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) has completed enrollment for its Phase 1b/2a clinical trial, the PACIFIC Study, which is evaluating LP352 for the treatment of Developmental and Epileptic Encephalopathies (DEEs). The study has enrolled 52 participants and aims to assess the safety and tolerability of LP352. Topline results are expected around year-end 2023.
August 23, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Longboard Pharmaceuticals has completed enrollment for its PACIFIC Study, which is a positive step towards the development of LP352. This could potentially boost investor confidence in the company's ability to innovate and deliver results.
The completion of enrollment for the PACIFIC Study indicates progress in Longboard's clinical trials. This could potentially lead to positive outcomes for the company, including the successful development and eventual approval of LP352. This news could positively impact the company's stock as it shows progress in their pipeline, which could boost investor confidence.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100